John Chandler
Cardiovascular Disease · New Haven, CTNPI 1740262419
Payments from drug & device makers
Across 75 payments — averaging $24.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$277
- Novartis$180
- Johnson & Johnson$162
- Amarin Pharma, Inc.$159
- Abbott$156
- Merck$138
- plus $785 from 15 others
What the payments were for
- Food & beverage$1,82998%
- Education$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $277 |
| Novartis | 7 | $180 |
| Johnson & Johnson | 9 | $162 |
| Amarin Pharma, Inc. | 5 | $159 |
| Abbott | 2 | $156 |
| Merck | 3 | $138 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| AstraZeneca | 6 | $100 |
| Pfizer | 5 | $68 |
| Boehringer Ingelheim | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $25 |
| Cvrx, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$138
- Inpefa$125
- Repatha$120
- VERQUVO$106
- ENTRESTO$101
How this compares
$1,857 in reported general payments places this provider in the 50th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 16 | $12,313 |
| EliquisApixaban | 13 | $9,268 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $8,163 |
| Ezetimibe | 53 | $896 |
| Rosuvastatin Calcium | 36 | $304 |
| Metoprolol Succinate | 27 | $278 |
| Losartan Potassium | 33 | $189 |
| Lisinopril | 15 | $184 |
| Spironolactone | 23 | $155 |
| Furosemide | 17 | $76 |
| Amlodipine Besylate | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $100 | $12,31316 claims |
| PfizerEliquis | $68 | $9,26813 claims |
| Esperion Therapeutics, Inc.Nexlizet | $47 | $8,16311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in New Haven
- Harlan KrumholzNew Haven$4M
- Jeffery TestaniNew Haven$3.4M
- Nihar DesaiNew Haven$3.2M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Carlos Mena-HurtadoNew Haven$665K
- John StendahlNew Haven$419K
- Tariq AhmadNew Haven$317K
- Rachel LampertNew Haven$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.